Pfizer’s Humira Biosimilar Displays Positive Top Line Results
PF-06410293 met primary endpoints during clinical trials and demonstrated similar efficacy to its reference product.
Results from a REFLECTIONS B538-02 trial with Pfizer’s investigational Humira (adalimumab) biosimilar, PF-06410293, showed that the drug met its primary endpoint, and demonstrated similar efficacy to its reference product. PF-06410293 is being evaluated in combination with methotrexate as a treatment for moderate to severe rheumatoid arthritis, the company said in a Jan. 5, 2017 announcement.
PF-06410293 is Pfizer’s second proposed inflammation biosimilar. The company’s pipeline consists of eight biosimilar molecules in mid- to late-stage development. Pfizer also said it has several other biosimilar molecules currently in early-stage development. Pfizer will likely face competition in the Humira biosimilar market. FDA approved the first biosimilar to Humira, Amjevita (adalimumab-atto), marketed by Amgen in the United States, in late September 2016.
Source: Pfizer
Texas' MD Anderson Cancer Center Creates New Cell Therapy Institute
November 11th 2024With the launch of the Institute for Cell Therapy Discovery and Innovation, the MD Anderson Cancer Center will bring together expertise in developing cell therapies for cancer, autoimmune diseases, and infections.
